




September 3, 1999 09:29 P2:34

Dr. Elizabeth Yetley
Office of Special Nutritionals (HFS-450)
Food and Drug Administration
200 C Street, S.W.
Washington D.C. 20204



Re: Fulfillment of Reporting Obligation
Under 21 U.S.C. & 343© and 21 CFR & 101.93

Dear Dr. Yetley:

E'OLA International, in accordance with 21 U.S.C. & 343© and 21 CFR & 101.93, hereby submits an original and two copies of its notification of its product marketing with the statement presented below. E'OLA International retains scientific documents supporting the statements.

1. Supplement Brand Name: **Meta-CLA**
2. Supplemental Ingredient(s) **Conjugated Linoleic Acid**
that is the subject of the statement:
3. Text Of Statement Of Nutritional Support: **"CLA is an essential fatty acid which scientists have discovered exerts a positive effect on fat metabolism. CLA has been shown to help inhibit the manufacture of fat and make it easier to get fact out of storage."**

In accordance with 21 U.S.C. & 343© and 21 CFR & 101.93©, each of the above statements will be followed by an asterisk that will cross-reference to another asterisk on the very same panel or page next to which the following statement will appear in the box in bold face type: **"These statements have not been evaluated by the Food and Drug Administration. The product is not intended to diagnose, treat, cure or prevent any disease."**

Respectfully Submitted,

Wayne Reis
E'OLA International, Inc.
President

97S - 0162

67162
LET 4264